Wednesday, April 18, 2018 7:53:17 AM
After Hours Time (ET) After Hours Price After Hours Share Volume
17:58:19 $ .743 665
17:57:50 $ .745 50
17:57:50 $ .75 50
17:57:50 $ .75 25
17:08:29 $ .795 400
17:08:29 $ .795 100
17:01:00 $ .793 1
16:50:29 $ .74 445
16:50:28 $ .74 500
16:50:27 $ .74 2,000
16:50:24 $ .739 1,637
16:50:22 $ .739 500
16:50:12 $ .739 150
16:50:12 $ .739 100
16:50:03 $ .739 500
16:49:18 $ .739 400
16:49:18 $ .739 100
16:48:54 $ .739 900
16:48:54 $ .739 100
16:48:40 $ .741 500
16:48:40 $ .75 10
16:46:36 $ .741 4,387
16:46:31 $ .741 100
16:46:31 $ .741 3,000
16:44:51 $ .75 500
16:43:56 $ .75 73
16:43:26 $ .75 400
16:42:48 $ .75 50
16:42:36 $ .75 2
16:41:27 $ .75 1,996
16:39:09 $ .75 1,000
16:39:09 $ .76 1
16:37:59 $ .775 288
16:10:16 $ .79 500
https://www.nasdaq.com/symbol/alt/after-hours
ALT
Recent ALT News
- CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes • GlobeNewswire Inc. • 09/10/2024 05:09:49 PM
- Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes • GlobeNewswire Inc. • 09/10/2024 11:45:00 AM
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:05:08 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:14:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:08:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:03:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:07:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:04:52 AM
- Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:45:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:40:41 PM
- Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology • GlobeNewswire Inc. • 07/25/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Altimmune to Participate at Leerink Partners Therapeutics Forum • GlobeNewswire Inc. • 07/02/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/23/2024 05:45:00 PM
- Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 08:45:00 PM
- Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM